Search

Drinabant

AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.

Chlormadinone acetate

However, the use of these drugs was associated with the development of mammary tumors in dogs. In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products. … Chlormadinone acetate is a progesterone derivative first synthesized in 1961.

Bisegliptin

It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

Fosfructose

Glyphosate

Rhodamine 6G

NGX267

NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

Difloxacin

However, it presents a reduced efficacy when compared to other fluoroquinolone antibacterials. … Difloxacin is a synthetic fluoroquinolone used in veterinary. As an antibacterial, it presents a broad bactericidal spectrum and its effects are dependent on its concentration.

NM-702

M-702 is an orally active inhibitor of phosphodiesterase and thromboxane synthetase. … Therapeutic options to improve exercise performance in these patients are limited

Lesopitron

Lesopitron is an anxiolytic with pre- and post-synaptic 5-HT1A agonist activity, which is under development by Esteve.